Meet the Team
We are a team of dedicated business and scientific experts, ready to develop superior biopharmaceuticals. Our management has a proven track record in out-licensing the entire products to global pharmaceutical and biotech companies.
Uli Binder, M.Sc.
Uli Binder brings more than 15 years of experience in early stage biopharmaceutical development. By combining his background in protein engineering and his entrepreneurial skills, he co-founded XL-protein in 2009 and served as its Chief Technology Officer. In this role, he refined and successfully commercialized the proprietary PASylation® technology. He studied Molecular Biotechnology & Business Administration and accomplished his Ph.D. studies at the Technical University of Munich.
Michaela Gebauer, Ph.D.
A Biochemist by training, she has spent over 15 years in drug discovery and development, with a focus on protein chemistry & protein design. Before joining XL-protein in 2014, Michaela was a post-doctoral fellow at Boehringer Ingelheim, focusing on lead discovery and optimization of novel protein molecules by phage display across various therapeutic areas. She obtained her PhD in Protein Engineering from the Technical University of Munich.
Claus Schalper, MBA
Claus started his career at Arthur Andersen and subsequently led two IT companies as CEO. He co-founded Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) with Prof. Dr. Arne Skerra in 2001 and was CFO until its listing in the US (2014). In 2009, he also served as CEO for Pieris, closing this Company`s Allergan deal as well as preparing for its strategic partnership with Sanofi.
Arne Skerra, Ph.D., Professor
Dr. Arne Skerra is Professor at the Technical University of Munich and a leading expert in therapeutic protein design. Beside PASylation®, he invented several other commercially successful technologies, such as bacterially produced antibody fragments, Anticalins® and the Strep-tag®.